Ann: Mernova Awarded Craft Designation with OCS, page-39

Fair commentary from a non-holder. Beats the usual garbage spewed by other non-holders.

CPH is only really beginning it's journey this year, with sophisticated/institutional investors John Hancock, S3, L1 Global Master supporting at 19c and committed to the journey. The psychedelics expansion in mental health treatment is an excellent opportunity, provided the phase 2 and 3 trials go well but on the cannabis front - I agree far more revenue is needed to justify the current market cap.

US reform will be the catalyst needed for CPH expansion and profitability I reckon.

Agree that the paid ads are high, but I'd like to see more aggressive marketing ahead of the OTC listing coming up in the next 2-3 weeks. Will have to wait and see how the US market rates the SP in the coming weeks.